Regulus Therapeutics Inc (NASDAQ:RGLS)
| 0.216 Delayed Data As of Jan 27 |  +0.0009 / +0.42%Today’s Change | 0.19 Today|||52-Week Range 2.32 | -31.43% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Other | MARKET CAP $19.5M |
Company Description
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.
Contact Information
Regulus Therapeutics, Inc. 4224 Campus Point Court San Diego California 92121 |
Employees
Shareholders
| Mutual fund holders | 9.43% |
| Other institutional | 7.25% |
| Individual stakeholders | 10.66% |
Top Executives
| Joseph P. Hagan | President, Chief Executive Officer & Director |
| Crispina Calsada | Chief Financial Officer |
| Denis Drygin | Chief Scientific Officer |
| Christopher Aker | Secretary, Senior Vice President & General Counsel |
| Daniel Penksa | Chief Accounting Officer & Controller |
